英国风湿科医生对痛风的管理:英国风湿病学会全国审计
该审计评估英国风湿科医生对新转诊痛风患者的管理与基于证据的最佳实践推荐的一致性,共纳入91个风湿科门诊的434例患者。多数审计标准符合良好,但12个月内仅45%和25%的患者分别达到血清尿酸≤360和<300 μmol/l。作者认为风湿科医生应帮助确保优化降尿酸治疗以达到目标血清尿酸水平。
要点
- 12个月内血清尿酸≤360 μmol/l者占45%,<300 μmol/l者占25%。
- 有降尿酸治疗指征者中76%继续或启动降尿酸治疗。
- 开始降尿酸治疗者中94%同时处方预防治疗。
核心结论
- 英国风湿科医生对痛风的管理在大多数审计标准上与指南一致性良好,但12个月内达到目标血清尿酸水平的患者不足一半。
- 作者认为风湿科医生应帮助确保优化降尿酸治疗以达到目标血清尿酸水平,从而使患者获益。
研究设计与样本
- 该研究为英国风湿病学会全国审计,收集8周期间新转诊至英国风湿科门诊的患者数据。
- 基线收集人口学、诊断方法、临床特征、合并症、降尿酸治疗、预防治疗和血液检查,12个月后收集最近一次血清尿酸水平。
- 管理情况与源自2006年EULAR推荐、2007年英国风湿病学会/英国风湿病卫生专业人员指南和NICE非布司他技术评估的审计标准进行比较。
主要发现
- 共收集91个风湿科434例患者的数据,平均年龄59.8岁,82%为男性,13%经晶体证实诊断。
- 106例使用利尿剂者中29%减少或停用利尿剂;有1项或以上降尿酸治疗指征者中76%继续或启动降尿酸治疗。
- 158例开始别嘌醇者中最常见起始剂量为每日100 mg(82%);估算肾小球滤过率<60 ml/min者中最高起始剂量为每日100 mg。
- 199例开始降尿酸治疗者中94%同时处方预防治疗;50例开始促尿酸排泄药或非布司他者中84%既往用过别嘌醇;44例开始非布司他者中18%有心脏病史。
- 12个月时血清尿酸≤360和<300 μmol/l分别由45%和25%的患者达到。
关键数值与推荐
- 审计标准源自2006年EULAR推荐、2007年英国风湿病学会/英国风湿病卫生专业人员指南和NICE非布司他技术评估。
- 有1项或以上降尿酸治疗指征者中76%继续或启动降尿酸治疗。
- 开始降尿酸治疗者中94%同时处方预防治疗。
- 12个月时血清尿酸≤360 μmol/l者占45%,<300 μmol/l者占25%。
临床怎么用
- 作者认为风湿科医生应帮助确保优化降尿酸治疗以达到目标血清尿酸水平,从而使患者获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the concordance of gout management by UK rheumatologists with evidence-based best-practice recommendations. METHODS: Data were collected on patients newly referred to UK rheumatology out-patient departments over an 8-week period. Baseline data included demographics, method of diagnosis, clinical features, comorbidities, urate-lowering therapy (ULT), prophylaxis and blood tests. Twelve months later, the most recent serum uric acid level was collected. Management was compared with audit standards derived from the 2006 EULAR recommendations, 2007 British Society for Rheumatology/British Health Professionals in Rheumatology guideline and the National Institute for Health and Care Excellence febuxostat technology appraisal. RESULTS: Data were collected for 434 patients from 91 rheumatology departments (mean age 59.8 years, 82% male). Diagnosis was crystal-proven in 13%. Of 106 taking a diuretic, this was reduced/stopped in 29%. ULT was continued/initiated in 76% of those with one or more indication for ULT. One hundred and fifty-eight patients started allopurinol: the starting dose was most commonly 100 mg daily (82%); in those with estimated glomerular filtration rate <60 ml/min the highest starting dose was 100 mg daily. Of 199 who started ULT, prophylaxis was co-prescribed for 94%. Fifty patients started a uricosuric or febuxostat: 84% had taken allopurinol previously. Of 44 commenced on febuxostat, 18% had a history of heart disease. By 12 months, serum uric acid levels ⩽360 and <300 μmol/l were achieved by 45 and 25%, respectively. CONCLUSION: Gout management by UK rheumatologists concords well with guidelines for most audit standards. However, fewer than half of patients achieved a target serum uric level over 12 months. Rheumatologists should help ensure that ULT is optimized to achieve target serum uric acid levels to benefit patients.
引用
- Roddy E, Packham J, Obrenovic K, et al. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018. PMID: 29447370. doi:10.1093/rheumatology/kex521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。